Trial · NCT03242252
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in HbA1c at Week 26 | Placebo | -0.22 | Standard Error 0.061 | percentage of HbA1c | |
| Change From Baseline in HbA1c at Week 26 | Sotagliflozin 200 mg | -0.32 | Standard Error 0.060 | percentage of HbA1c | |
| Change From Baseline in HbA1c at Week 26 | Sotagliflozin 400 mg | -0.46 | Standard Error 0.060 | percentage of HbA1c | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Placebo | -0.374 | Standard Error 0.1949 | millimole per liter (mmol/L) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Sotagliflozin 200 mg | -0.961 | Standard Error 0.1715 | millimole per liter (mmol/L) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 | Sotagliflozin 400 mg | -0.852 | Standard Error 0.1668 | millimole per liter (mmol/L) | |
| Change From Baseline in SBP for Participants With Baseline SBP ≥130 mmHg at Week 12 | Placebo | -5.18 | Standard Error 1.462 | mmHg | |
| Change From Baseline in SBP for Participants With Baseline SBP ≥130 mmHg at Week 12 | Sotagliflozin 200 mg | -7.46 | Standard Error 1.597 | mmHg | |
| Change From Baseline in SBP for Participants With Baseline SBP ≥130 mmHg at Week 12 | Sotagliflozin 400 mg | -7.71 | Standard Error 1.247 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Placebo | -3.31 | Standard Error 1.037 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Sotagliflozin 200 mg | -4.91 | Standard Error 1.010 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Sotagliflozin 400 mg | -4.94 | Standard Error 0.983 | mmHg | |
| Change From Baseline in Body Weight at Week 26 | Placebo | -0.38 | Standard Error 0.262 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 26 | Sotagliflozin 200 mg | -1.66 | Standard Error 0.246 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 26 | Sotagliflozin 400 mg | -1.20 | Standard Error 0.257 | kilogram (kg) | |
| Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g) | Placebo | -18.71 | Standard Error NA | percent change | |
| Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g) | Sotagliflozin 200 mg | -43.68 | Standard Error NA | percent change | |
| Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio (UACR) at Week 26 in Participants With Baseline UACR >30 Milligrams Per Gram (mg/g) | Sotagliflozin 400 mg | -48.12 | Standard Error NA | percent change | |
| Percentage of Participants With HbA1c <6.5% at Week 26 | Placebo | 4.2 | percentage of participants | ||
| Percentage of Participants With HbA1c <6.5% at Week 26 | Sotagliflozin 200 mg | 5.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03242252/results